search
Back to results

Nutritional Intervention for Endometriosis

Primary Purpose

Endometriosis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Plant-based Intervention Group
Sponsored by
Physicians Committee for Responsible Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endometriosis focused on measuring endometriosis, plant-based, vegan, low-fat, diet, nutrition

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Women with a surgical, imaging, or clinical diagnosis of endometriosis
  2. Age 18-45 years
  3. Stable health condition and medications for past 3 months
  4. Modified Biberoglu and Behrman (B&B) pelvic pain score of at least 5/9
  5. Able to follow a plant-based diet for 12 weeks
  6. Willing to be randomly assigned to either a plant-based group or a control group that will not make any dietary changes for 12 weeks

Exclusion Criteria:

  1. Body mass index ≥ 40 kg/m2
  2. Smoking or drug abuse during the past six months
  3. Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use
  4. Unstable medical or psychiatric illness
  5. Already following a plant-based diet
  6. Pregnant or breastfeeding, or plans of pregnancy within the study period
  7. Hysterectomy or ovariectomy
  8. Fibroids, ovarian cysts, pelvic inflammatory disease
  9. Endocrine inflammatory conditions, such as Cushing's syndrome, Hashimoto's thyroiditis, Graves' disease, type 1 diabetes mellitus, and Addison's disease
  10. Lack of English fluency
  11. Unable or unwilling to participate in all components of the study
  12. Evidence of an eating disorder

Sites / Locations

  • Physicians Committee for Responsible MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Plant-based Intervention Group

Control Group

Arm Description

Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.

Control group participants will be asked to maintain their usual diet for the duration of the 12-week study period. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant. At the conclusion of the 12 weeks, control group participants will be offered instruction in the plant-based diet.

Outcomes

Primary Outcome Measures

Modified Biberoglu and Behrman Scale: change from baseline
Endometriosis-specific pain scale will be used. For inclusion in study, participants require a score of at least 5/9.
Endometriosis Health Profile (EHP-30): change from baseline
The EHP-30 questionnaire is the only validated quality of life questionnaire for the use in endometriosis.
Inflammatory biomarkers: change from baseline
Blood tests for biomarkers of inflammation (hsCRP, TNF-alpha, IL-1 beta and IL-6).

Secondary Outcome Measures

Body weight: change from baseline
Weight will be measured using a self-calibrating scale (Renpho).
Blood lipids: change from baseline
Change in blood lipids assessed via blood tests including lipid panels.
Estrogen levels: change from baseline
Estradiol, free estradiol, and sex hormone binding globulin (SHBG) will be measured through blood tests.
Gut microbiome composition: change from baseline
Participants will collect stool samples for microbiome analysis. Sample collection will be carried out using home collection procedures with samples returned through local post. The participants will apply a small smear to the tips of a swab from used toilet paper. The swab will, in turn, be used to transfer the smear to a fecal occult blood test (FOBT) card that will be returned by mail to a laboratory for analysis.
Biomarkers of endometriosis and inflammation: change from baseline
Plasma levels of brain-derived neurotrophic factor (BDNF) and IL-10 will be measured through blood tests.

Full Information

First Posted
December 14, 2021
Last Updated
September 27, 2022
Sponsor
Physicians Committee for Responsible Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05175248
Brief Title
Nutritional Intervention for Endometriosis
Official Title
A Randomized Controlled Trial of a Nutritional Intervention for Endometriosis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 2, 2022 (Actual)
Primary Completion Date
July 2025 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Physicians Committee for Responsible Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
In a 12-week parallel study, women with a verified diagnosis of endometriosis will be randomly assigned to follow a low-fat plant-based diet or to stay on their usual diets for 12 weeks. Participants in both groups will be asked to make no changes to their exercise patterns for the study period. Changes in pain, quality of life, and inflammatory biomarkers from baseline to final will be the primary outcomes. Secondary outcomes will include changes in body weight, blood lipids, gut microbiome composition, and hormonal changes.
Detailed Description
Endometriosis is a chronic, painful condition that affects 5-10% of reproductive aged women. It is characterized by the presence of endometrial cells outside the uterus, causing pain and infertility. Current therapies to temporarily control symptoms include surgery and medical options with significant side effects. Women with endometriosis may have several surgeries by their mid-20s. The medical costs associated with endometriosis in the US alone are about $3.6 billion annually, and the total annual health care cost associated with endometriosis in 2002 was $22 billion, one-third of which is direct health care costs, with two-thirds attributed to loss of productivity. Diet may play important roles in endometriosis through its effect on circulating estrogen concentrations and inflammatory processes. Reduced fat intake and increased fiber intake have been shown to reduce estrogen levels, a key determinant of endometriosis activity. Some evidence suggests a pathogenic role for the gut microbiome, which influences the mucosal immune system and pelvic inflammation. The microbiome is responsive to short term dietary intervention, although long term changes have not been well characterized. Therefore, the investigators propose a novel intervention strategy using a plant-based diet to improve pain, inflammation, and quality of life. The morbidity caused by endometriosis is substantial in terms of pain, reduced quality of life, lost productivity, and effects on relationships. Current medical therapies are limited in efficacy and have major side effects. Typical palliative surgery does not cure endometriosis. Better understanding of diet's ability to influence the disease process has the potential to improve quality of life and daily functioning without the cost and side effects of current therapies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometriosis
Keywords
endometriosis, plant-based, vegan, low-fat, diet, nutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Plant-based Intervention Group
Arm Type
Experimental
Arm Description
Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Control group participants will be asked to maintain their usual diet for the duration of the 12-week study period. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant. At the conclusion of the 12 weeks, control group participants will be offered instruction in the plant-based diet.
Intervention Type
Behavioral
Intervention Name(s)
Plant-based Intervention Group
Intervention Description
Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
Primary Outcome Measure Information:
Title
Modified Biberoglu and Behrman Scale: change from baseline
Description
Endometriosis-specific pain scale will be used. For inclusion in study, participants require a score of at least 5/9.
Time Frame
at baseline and at 12 weeks
Title
Endometriosis Health Profile (EHP-30): change from baseline
Description
The EHP-30 questionnaire is the only validated quality of life questionnaire for the use in endometriosis.
Time Frame
at baseline and at 12 weeks
Title
Inflammatory biomarkers: change from baseline
Description
Blood tests for biomarkers of inflammation (hsCRP, TNF-alpha, IL-1 beta and IL-6).
Time Frame
at baseline and at 12 weeks
Secondary Outcome Measure Information:
Title
Body weight: change from baseline
Description
Weight will be measured using a self-calibrating scale (Renpho).
Time Frame
at baseline and at 12 weeks
Title
Blood lipids: change from baseline
Description
Change in blood lipids assessed via blood tests including lipid panels.
Time Frame
at baseline and at 12 weeks
Title
Estrogen levels: change from baseline
Description
Estradiol, free estradiol, and sex hormone binding globulin (SHBG) will be measured through blood tests.
Time Frame
at baseline and at 12 weeks
Title
Gut microbiome composition: change from baseline
Description
Participants will collect stool samples for microbiome analysis. Sample collection will be carried out using home collection procedures with samples returned through local post. The participants will apply a small smear to the tips of a swab from used toilet paper. The swab will, in turn, be used to transfer the smear to a fecal occult blood test (FOBT) card that will be returned by mail to a laboratory for analysis.
Time Frame
at baseline and at 12 weeks
Title
Biomarkers of endometriosis and inflammation: change from baseline
Description
Plasma levels of brain-derived neurotrophic factor (BDNF) and IL-10 will be measured through blood tests.
Time Frame
at baseline and at 12 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women with a surgical, imaging, or clinical diagnosis of endometriosis Age 18-45 years Stable health condition and medications for past 3 months Modified Biberoglu and Behrman (B&B) pelvic pain score of at least 5/9 Able to follow a plant-based diet for 12 weeks Willing to be randomly assigned to either a plant-based group or a control group that will not make any dietary changes for 12 weeks Exclusion Criteria: Body mass index ≥ 40 kg/m2 Smoking or drug abuse during the past six months Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use Unstable medical or psychiatric illness Already following a plant-based diet Pregnant or breastfeeding, or plans of pregnancy within the study period Hysterectomy or ovariectomy Fibroids, ovarian cysts, pelvic inflammatory disease Endocrine inflammatory conditions, such as Cushing's syndrome, Hashimoto's thyroiditis, Graves' disease, type 1 diabetes mellitus, and Addison's disease Lack of English fluency Unable or unwilling to participate in all components of the study Evidence of an eating disorder
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Macy Sutton, MS
Phone
202-527-7385
Email
msutton@pcrm.org
First Name & Middle Initial & Last Name or Official Title & Degree
Tatiana Znayenko-Miller, MS
Phone
202-527-7317
Email
tznayenkomiller@pcrm.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hana Kahleova, MD, PhD
Organizational Affiliation
Physicians Committee for Responsible Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Neal Barnard, MD
Organizational Affiliation
Physicians Committee for Responsible Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Physicians Committee for Responsible Medicine
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Macy Sutton, MS
Phone
202-527-7385
Email
msutton@pcrm.org
First Name & Middle Initial & Last Name & Degree
Danielle Holtz, BS
Phone
2025277363
Email
dholtz@pcrm.org
First Name & Middle Initial & Last Name & Degree
Hana Kahleova, MD, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
15980014
Citation
Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E; ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005 Oct;20(10):2698-704. doi: 10.1093/humrep/dei135. Epub 2005 Jun 24.
Results Reference
background
PubMed Identifier
22562031
Citation
Khanaki K, Nouri M, Ardekani AM, Ghassemzadeh A, Shahnazi V, Sadeghi MR, Darabi M, Mehdizadeh A, Dolatkhah H, Saremi A, Imani AR, Rahimipour A. Evaluation of the relationship between endometriosis and omega-3 and omega-6 polyunsaturated fatty acids. Iran Biomed J. 2012;16(1):38-43. doi: 10.6091/ibj.1025.2012.
Results Reference
background
PubMed Identifier
9572232
Citation
Marik JJ. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol. 1998 May;91(5 Pt 1):793-4. doi: 10.1097/00006250-199805000-00029. No abstract available.
Results Reference
background
PubMed Identifier
18165396
Citation
Stratton P, Sinaii N, Segars J, Koziol D, Wesley R, Zimmer C, Winkel C, Nieman LK. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008 Jan;111(1):88-96. doi: 10.1097/01.AOG.0000297307.35024.b5.
Results Reference
background
PubMed Identifier
23427182
Citation
Rogers PA, D'Hooghe TM, Fazleabas A, Giudice LC, Montgomery GW, Petraglia F, Taylor RN. Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis In Montpellier, France. Reprod Sci. 2013 May;20(5):483-99. doi: 10.1177/1933719113477495. Epub 2013 Feb 20.
Results Reference
background
PubMed Identifier
8039147
Citation
Goldin BR, Woods MN, Spiegelman DL, Longcope C, Morrill-LaBrode A, Dwyer JT, Gualtieri LJ, Hertzmark E, Gorbach SL. The effect of dietary fat and fiber on serum estrogen concentrations in premenopausal women under controlled dietary conditions. Cancer. 1994 Aug 1;74(3 Suppl):1125-31. doi: 10.1002/1097-0142(19940801)74:3+3.0.co;2-5.
Results Reference
background
PubMed Identifier
27541692
Citation
Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016 Aug 19;14(8):e1002533. doi: 10.1371/journal.pbio.1002533. eCollection 2016 Aug.
Results Reference
background
PubMed Identifier
16741115
Citation
Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science. 2006 Jun 2;312(5778):1355-9. doi: 10.1126/science.1124234.
Results Reference
background
PubMed Identifier
26002030
Citation
Longman RS, Littman DR. The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity. Curr Opin Rheumatol. 2015 Jul;27(4):381-7. doi: 10.1097/BOR.0000000000000190.
Results Reference
background
PubMed Identifier
22674334
Citation
Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012 Jun 8;336(6086):1268-73. doi: 10.1126/science.1223490. Epub 2012 Jun 6.
Results Reference
background
PubMed Identifier
18854238
Citation
Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008 Oct 16;4(4):337-49. doi: 10.1016/j.chom.2008.09.009.
Results Reference
background
PubMed Identifier
20620945
Citation
Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010 Jun 25;32(6):815-27. doi: 10.1016/j.immuni.2010.06.001.
Results Reference
background
PubMed Identifier
16009137
Citation
Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005 Jul 15;122(1):107-18. doi: 10.1016/j.cell.2005.05.007.
Results Reference
background
PubMed Identifier
18509436
Citation
Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008 May 29;453(7195):620-5. doi: 10.1038/nature07008.
Results Reference
background
PubMed Identifier
16267321
Citation
Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005 Nov 3;353(18):1899-911. doi: 10.1056/NEJMoa043802.
Results Reference
background
PubMed Identifier
20534435
Citation
Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1(Suppl 1):4680-7. doi: 10.1073/pnas.1002611107. Epub 2010 Jun 3.
Results Reference
background
PubMed Identifier
22719852
Citation
Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, Ross FJ, McCoy CO, Bumgarner R, Marrazzo JM, Fredricks DN. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One. 2012;7(6):e37818. doi: 10.1371/journal.pone.0037818. Epub 2012 Jun 18.
Results Reference
background
PubMed Identifier
24336217
Citation
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 Jan 23;505(7484):559-63. doi: 10.1038/nature12820. Epub 2013 Dec 11.
Results Reference
background
PubMed Identifier
30625295
Citation
Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, Singh SS, Taylor HS. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019 Apr;220(4):354.e1-354.e12. doi: 10.1016/j.ajog.2018.12.039. Epub 2019 Jan 6.
Results Reference
background
PubMed Identifier
20567196
Citation
Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010 Jul;116(1):223-236. doi: 10.1097/AOG.0b013e3181e8b073. No abstract available.
Results Reference
background
PubMed Identifier
1786335
Citation
Ridout MS. Testing for random dropouts in repeated measurement data. Biometrics. 1991 Dec;47(4):1617-9; discussion 1619-21.
Results Reference
background
Citation
Paik, MC, Quasi-likelihood regression models with missing covariates, Biometrika 1996: Vol. 83, No. 4., 825-834
Results Reference
background
PubMed Identifier
3153505
Citation
Gibbons RD, Hedeker D, Waternaux C, Davis JM. Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull. 1988;24(3):438-43. No abstract available.
Results Reference
background
Citation
Hedeker D, Gibbons R, Waternaux C. Sample size estimation for longitudinal designs with attrition: Comparing time-related contrasts between two groups. Journal of Educational and Behavioral Statistics. 1999; 24:70-93.
Results Reference
background
Citation
Westfall PH and Young SS. (1993). Resampling-based Multiple Testing: Examples and Methods for Multiple P-value Adjustment. John Wiley & Sons: New York.
Results Reference
background

Learn more about this trial

Nutritional Intervention for Endometriosis

We'll reach out to this number within 24 hrs